CVS Health (CVS) is overhauling its direct-to-consumer weight management programme, cutting the price of MinuteClinic weight-management visits to just $29 per appointment.
The healthcare giant is also rolling out pharmacist support across its entire network of 9,000 U.S. pharmacy locations as part of the expanded initiative.
CVS has entered a new pricing collaboration with Eli Lilly and Company for eligible patients taking Zepbound and Foundayo, two of Lilly’s weight-loss treatments.
The company said the changes are designed to connect scheduling, clinical evaluation, medication access, and pharmacist support into a single, seamless patient experience.
CVS explicitly said the new model would operate without separate memberships, mail-order-only access, or fragmented handoffs between its MinuteClinic and CVS Pharmacy businesses.
The Lilly collaboration also connects to the CMS Medicare GLP-1 Bridge program, which runs through December 31, 2027, and allows eligible Medicare beneficiaries to access certain GLP-1 medications for $50 a month.
CVS disclosed the Lilly collaboration on the same day it reported its second-quarter 2026 financial results, posting net income of $2.98 billion for the period.
The company beat Wall Street’s earnings and revenue estimates by a wide margin, reflecting strength across its pharmacy, pharmacy benefit management, and insurance segments.
CVS raised its full-year adjusted earnings guidance to a range of $7.90 to $8.10 per share, up from a prior range of $7.30 to $7.50, representing a significant uplift in expectations.
The company cited its 2025 Rx Report in framing the central role of pharmacists in the new model, noting that nearly half of consumers prioritise personalised care at the pharmacy.
Embedded pharmacist support is positioned as a key differentiator for both treatment initiation and long-term patient persistence on GLP-1 medications.
The move comes as employer-sponsored weight-loss GLP-1 coverage remains relatively limited, with only roughly 20% of large firms currently offering such benefits to employees.
CVS appears to be betting that removing cost and access barriers will accelerate adoption of GLP-1 therapies among a broader patient population across the United States.